3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
CNS
2
Breast
2
Conditions
Prostatic Neoplasms
28
Neoplasm Metastasis
6
Recurrence
5
Breast Neoplasms
4
Stomach Neoplasms
3
Prostate Cancer Metastatic
3
Neoplastic Cells, Circulating
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer, Hereditary, 7
1
Penile Neoplasms
1
Nonseminomatous germ cell tumor
1
Metastatic Castration-resistant Prostate Cancer, MCRPC
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lung Neoplasms
1
Liposarcoma
1
Hormone-Resistant Prostate Cancer
1
Hormone Refractory Prostate Cancer
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Diarrhea
1
Interventions
Temozolomide
73
Bevacizumab
58
Radiotherapy
40
Radiosurgery
28
Carboplatin
23
Nivolumab
17
Etoposide
17
Cisplatin
17
pembrolizumab
16
Irinotecan
16
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Cyclophosphamide
14
Carmustine
14
Pemetrexed
13
Topotecan
10
Surgical Procedures, Operative
10
Capecitabine
10
Lapatinib
9
Filgrastim
9
Trastuzumab
8
Thalidomide
8
Sunitinib
8
Paclitaxel
8
Lomustine
8
Aminolevulinic Acid
8
encorafenib
7
binimetinib
7
Vincristine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Brain Neoplasms
×
cabazitaxel
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled
NCT01913067
2014-07-24
CRANIAL
Jules Bordet Institute
Phase 2
Withdrawn